$18.8MRound, 12 November 2025
Funds a 2026 proof-of-concept trial on biomarkers for amyloid-depleting Alzheimer's treatments.
- Amount
- $18.8M
- Announced
- 12 November 2025
- Lead
- Ava Investors
- Other investors
- Lichtsteiner Foundation, Zühlke Ventures
- Use of funds
- Funds a 2026 proof-of-concept trial on biomarkers for amyloid-depleting Alzheimer's treatments.
- Checked
- Announced by the company
- Sources
- Indivi raises EUR 16M businesswire.com
Indivi raises EUR 16M funding.tech.eu